Celgene to call $1 billion 2.125% notes, $400 million 2.3% notes

By Susanna Moon

Chicago, Oct. 31 – Celgene Corp. plans to call its $1 billion 2.125% senior notes due August 2018 and $400 million 2.3% senior notes due August 2018 using proceeds of a new issue.

The notes will be redeemed at par plus any make-whole interest.

Celgene plans to price senior notes under a shelf registration with the Securities and Exchange Commission, according to company announcement.

Remaining proceeds will be used for general corporate purposes, which may include further development of the company’s clinical and pre-clinical programs, capital expenditures, general corporate development activities, working capital and repurchases of common stock.

The global biopharmaceutical company is based in Summit, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.